Announcements Trials
Browse Landscape

Phase

Phase NA 36Phase 2 2Phase 1/2 2Phase EARLY_PHASE1 1Phase 3 1Phase 2/3 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 9Gastrointestinal 4Tumor-Agnostic 3Other hematologic neoplasm 3Genitourinary 2CNS 2Thoracic 1Other 1Gynecologic 1

Conditions

Prostatic Neoplasms 2Motor Activity 2Neoplasm Metastasis 1Fatigue 1

Interventions

Docetaxel 191Gemcitabine 148Prednisone 142pembrolizumab 125enzalutamide 119Abiraterone Acetate 108Nivolumab 107Cisplatin 103Magnetic Resonance Spectroscopy 100Radiotherapy 95Sunitinib 94Leuprolide 91Carboplatin 82Specimen Handling 71Androgen Antagonists 63bicalutamide 60Radiosurgery 60Paclitaxel 59Goserelin 59Ipilimumab 57Bevacizumab 57apalutamide 53Sorafenib 53acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51Everolimus 49cabozantinib 48abiraterone 46atezolizumab 45cabazitaxel 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Exercise × Genitourinary × Clear all
NCT02046837 2021-04-13

ADT Ex RCT

University Health Network, Toronto

Phase 2 Completed
59 enrolled
Genitourinary

Fatigue, Motor Activity, Prostatic Neoplasms

NCT00271687 2016-02-25

A Pilot Study of Exercise in Patients With Docetaxel-Based Chemotherapy for Hormone Refractory Prostate Cancer

AHS Cancer Control Alberta

Phase 2 Completed
30 enrolled
Genitourinary

Motor Activity, Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡